Key result
Transcutaneous auricular vagus nerve stimulation reduces IL-6 by ~38% versus sham in hospitalized COVID-19 patients.
Why the study?
Because taVNS has shown effectiveness in reducing inflammation and depression, this study evaluated its effect on inflammation, cardiac autonomic modulation, and clinical symptoms in individuals affected by COVID-19.
Does transcutaneous auricular vagus nerve stimulation reduce inflammatory markers and improve cardiac autonomic modulation and clinical symptoms in hospitalized adults with moderate or severe COVID-19?
RCT (n=52)
Single-blind (participants were blind to the treatment)
Randomized via www.randomizer.org by a researcher not involved in the treatments
No
Does transcutaneous auricular vagus nerve stimulation reduce inflammatory markers and improve cardiac autonomic modulation and clinical symptoms in hospitalized adults with moderate or severe COVID-19?
In hospitalized patients with moderate-to-severe COVID-19, 7 days of transcutaneous auricular vagus nerve stimulation significantly reduced systemic inflammatory markers (IL-6 and CRP) and depressive symptoms, but did not alter cardiac autonomic modulation (HRV) or physical COVID-19 symptoms.
Answers are grounded in this paper and cite their sources.
Supports taVNS to reduce inflammation in hospitalized COVID-19; extends vagal neuromodulation evidence to acute viral illness.
Transcranial auricular vagus nerve stimulation (taVNS) has shown effectiveness in reducing inflammation and depression. Thus, this study evaluated its effect on inflammation, cardiac autonomic modulation, and clinical symptoms in individuals affected by COVID-19. Methods: There were 52 randomized participants hospitalized with COVID-19 diagnosis who were to receive active (a-taVNS) or sham taVNS (s-taVNS) for 90 min twice a day for seven consecutive days. Interleukin 6 (IL-6), 10 (IL-10), cortisol, C-reactive protein (CRP), heart rate variability (HRV), and clinical symptoms were assessed before and after seven days of treatment. There were also seven- and fourteen-day follow-ups for clinical symptoms, including anxiety and depression levels, as well as a six-month follow-up for memory and attention levels. Results: There was significant reduction in CRP −23.9%, (95% CI −46.3 to −1.4) and IL-6 −37.7%, (95% CI −57.6 to −17.7) for the a-taVNS group. There were no changes in IL-10, cortisol levels, or in HRV results (p > 0.05) in both groups. There were no changes regarding clinical symptoms, except for a significant decrease in depression level (−2.85, 95% CI −5.44 to −0.27) in the a-taVNS group. Conclusion: taVNS showed effects on CRP, IL-6, and depression levels; however, it did not affect other clinical symptoms.
No takes yet. Share an insight, caveat, or question.
Corrêa et al. (2022) conducted an RCT in Hospitalized moderate or severe COVID-19 (n=52). Transcutaneous auricular vagus nerve stimulation (taVNS) vs. Sham transcutaneous auricular vagus nerve stimulation (equipment remained off) plus usual medical care was evaluated on Percentage change in Interleukin-6 (IL-6) from baseline to day 7 (MD -37.7%, 95% CI -57.6 to -17.7, p=<0.001). Transcutaneous auricular vagus nerve stimulation reduced IL-6 by 37.7% and CRP by 23.9% compared to sham in hospitalized COVID-19 patients, without affecting HRV.
Synapse has enriched 10 related papers. Consider them for comparative context: